Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population Pharmacokinetics and Pharmacogenetics of Ethambutol in Adult Patients Coinfected with Tuberculosis and HIV.

Antimicrobial agents and chemotherapy - 27 Jan 2020

Sundell Jesper, Bienvenu Emile, Birgersson Sofia, Äbelö Angela, Ashton Michael

Abstract excerpt

This study aimed to characterize the population pharmacokinetics and pharmacogenetics of ethambutol in tuberculosis-HIV-coinfected adult patients. Ethambutol plasma concentrations, determined by liquid chromatography-tandem mass spectrometry, in 63 patients receiving ethambutol as part of rifampin-based fixed-dose combination therapy for tuberculosis were analyzed using nonlinear mixed-effects modeling. A...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Antitubercular Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biological Availability

Share to Coinfection

Share to Cytochrome P-450 CYP1A2

Share to Ethambutol

Share to Rwanda

Share to Tuberculosis, Pulmonary

Source

Open in PubMed Open full text

Identifiers

PMID: 31712201
DOI: 10.1128/AAC.01583-19
PMCID: PMC6985744

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population Pharmacokinetics and Pharmacogenetics of Ethambutol in Adult Patients Coinfected with Tuberculosis and HIV.PMID 31712201Read ↗

A population approach of rifampicin pharmacogenetics and pharmacokinetics in Mexican patients with tuberculosis.Semantic proximity Read ↗

Rifampicin population pharmacokinetics and pharmacogenomic evaluation of SLCO1B1 gene in tuberculosis patients.Semantic proximity Read ↗

Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis.Semantic proximity Read ↗

Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand.Semantic proximity Read ↗

Genetic polymorphism related to ethambutol outcomes and susceptibility to toxicitySemantic proximity Read ↗

Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study.Semantic proximity Read ↗

Transporter and metabolizer gene polymorphisms affect fluoroquinolone pharmacokinetic parametersSemantic proximity Read ↗

Population Pharmacokinetic Modeling of Bedaquiline among Multidrug-Resistant Pulmonary Tuberculosis Patients from China.Semantic proximity Read ↗

Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients.Semantic proximity Read ↗

Population pharmacokinetics of isoniazid and dose recommendations in Mexican patients with tuberculosis.Semantic proximity Read ↗

Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models.Semantic proximity Read ↗

Model-Based Assessment of Variability in Isoniazid Pharmacokinetics and Metabolism in Patients Co-Infected With Tuberculosis and HIV: Implications for a Novel Dosing Strategy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.